IQVIA Holdings Inc. $IQV Shares Sold by Corsair Capital Management L.P.

Key Points

• Corsair Capital Management L.P. has significantly reduced its stake in IQVIA Holdings Inc. by 67.3%, bringing their total ownership to 7,105 shares, valued at approximately $1.25 million.
• Analysts have positive outlooks for IQVIA, with multiple firms raising their target prices; Truist Financial set a new target at $235.00 and 17 analysts rated the stock as a Buy.
• In recent earnings, IQVIA reported $2.81 earnings per share, exceeding estimates, with revenue of $4.02 billion, reflecting a year-over-year increase of 5.3%.

Corsair Capital Management L.P. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 67.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,105 shares of the medical research company's stock after selling 14,620 shares during the period. IQVIA makes up approximately 0.3% of Corsair Capital Management L.P.'s investment portfolio, making the stock its 28th biggest holding. Corsair Capital Management L.P.'s holdings in IQVIA were worth $1,253,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. American National Bank & Trust acquired a new stake in shares of IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the first quarter worth $33,000. Finally, ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IQV shares. Truist Financial boosted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Barclays boosted their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. UBS Group boosted their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Mizuho boosted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Trading Down 0.0%

Shares of IQVIA stock opened at $188.73 on Friday. The firm has a 50-day simple moving average of $176.32 and a two-hundred day simple moving average of $167.99. The company has a market cap of $32.08 billion, a P/E ratio of 27.31, a price-to-earnings-growth ratio of 2.07 and a beta of 1.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.